Flinton Capital Management LLC lessened its position in Edwards Lifesciences Corporation (NYSE:EW) by 34.7% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 10,030 shares of the medical research company’s stock after selling 5,338 shares during the period. Flinton Capital Management LLC’s holdings in Edwards Lifesciences Corporation were worth $1,186,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in the business. Prudential PLC bought a new position in shares of Edwards Lifesciences Corporation in the second quarter valued at approximately $238,000. Royal Bank of Canada lifted its holdings in shares of Edwards Lifesciences Corporation by 0.7% in the second quarter. Royal Bank of Canada now owns 1,319,848 shares of the medical research company’s stock valued at $156,059,000 after purchasing an additional 8,946 shares in the last quarter. AHL Partners LLP lifted its holdings in shares of Edwards Lifesciences Corporation by 11.0% in the second quarter. AHL Partners LLP now owns 54,629 shares of the medical research company’s stock valued at $6,460,000 after purchasing an additional 5,392 shares in the last quarter. Zurich Insurance Group Ltd FI lifted its holdings in shares of Edwards Lifesciences Corporation by 27.2% in the second quarter. Zurich Insurance Group Ltd FI now owns 44,729 shares of the medical research company’s stock valued at $5,289,000 after purchasing an additional 9,561 shares in the last quarter. Finally, Salem Investment Counselors Inc. lifted its holdings in shares of Edwards Lifesciences Corporation by 16.3% in the second quarter. Salem Investment Counselors Inc. now owns 1,419 shares of the medical research company’s stock valued at $168,000 after purchasing an additional 199 shares in the last quarter. 82.08% of the stock is owned by hedge funds and other institutional investors.

A number of research analysts have recently weighed in on the company. Bank of America Corporation raised their target price on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, July 27th. BidaskClub lowered Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. SunTrust Banks, Inc. lifted their price target on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a report on Monday, July 17th. Canaccord Genuity reiterated a “buy” rating and set a $155.00 price target (up from $150.00) on shares of Edwards Lifesciences Corporation in a report on Sunday, July 30th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $120.00 price target on shares of Edwards Lifesciences Corporation in a report on Saturday, September 30th. Seven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation currently has an average rating of “Buy” and a consensus target price of $120.75.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,300 shares of the stock in a transaction on Friday, September 29th. The stock was sold at an average price of $108.86, for a total value of $576,958.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael A. Mussallem sold 32,900 shares of the stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $115.99, for a total value of $3,816,071.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 182,201 shares of company stock worth $20,768,154. 2.13% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Flinton Capital Management LLC Trims Holdings in Edwards Lifesciences Corporation (EW)” was reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international copyright laws. The correct version of this piece can be accessed at https://www.watchlistnews.com/flinton-capital-management-llc-trims-holdings-in-edwards-lifesciences-corporation-ew/1615020.html.

Edwards Lifesciences Corporation (NYSE:EW) opened at 111.46 on Friday. The stock has a market capitalization of $23.54 billion, a PE ratio of 33.81 and a beta of 0.62. The stock has a 50 day moving average price of $111.90 and a 200 day moving average price of $110.77. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last announced its earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the Zacks’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The company had revenue of $842.00 million for the quarter, compared to analysts’ expectations of $839.16 million. During the same period last year, the firm earned $0.76 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW).

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.